Scholar Rock (NASDAQ:SRRK) Stock Rating Lowered by Wolfe Research

Scholar Rock (NASDAQ:SRRK) was downgraded by research analysts at Wolfe Research from an “outperform” rating to a “peer perform” rating in a research report issued on Thursday, Briefing.com reports.

Several other brokerages have also weighed in on SRRK. JPMorgan Chase & Co. increased their price objective on shares of Scholar Rock from $63.00 to $70.00 and gave the company an “overweight” rating in a research report on Monday, September 21st. Barclays downgraded shares of Scholar Rock from an “overweight” rating to a “cautious” rating in a report on Tuesday, September 15th. UBS Group reaffirmed a “buy” rating on shares of Scholar Rock in a report on Tuesday, September 15th. TD Cowen reiterated a “buy” rating on shares of Scholar Rock in a research note on Monday, September 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, October 15th. Three analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $67.67.

Scholar Rock Stock Down 2.9%

SRRK opened at $46.60 on Thursday. The stock’s fifty day simple moving average is $46.64 and its 200 day simple moving average is $48.23. Scholar Rock has a 1-year low of $29.35 and a 1-year high of $61.76. The stock has a market cap of $5.68 billion, a PE ratio of -13.87 and a beta of 0.78. The company has a current ratio of 7.02, a quick ratio of 7.02 and a debt-to-equity ratio of 0.77.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.30 million. During the same period last year, the firm earned ($0.90) earnings per share. As a group, research analysts expect that Scholar Rock will post -3.29 earnings per share for the current year.

Insider Transactions at Scholar Rock

In other news, Director Srinivas Akkaraju purchased 146,970 shares of Scholar Rock stock in a transaction that occurred on Monday, October 26th. The stock was acquired at an average cost of $41.59 per share, for a total transaction of $6,112,482.30. Following the purchase, the director directly owned 6,380,517 shares of the company’s stock, valued at $265,365,702.03. This trade represents a 2.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 10.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Scholar Rock during the second quarter worth $522,175,000. Redmile Group LLC grew its stake in shares of Scholar Rock by 73.7% in the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock valued at $445,715,000 after acquiring an additional 3,845,775 shares in the last quarter. Jennison Associates LLC grew its stake in shares of Scholar Rock by 19.5% in the first quarter. Jennison Associates LLC now owns 3,340,492 shares of the company’s stock valued at $164,219,000 after acquiring an additional 545,304 shares in the last quarter. Jupiter Topco LLC acquired a new position in shares of Scholar Rock in the second quarter valued at about $123,279,000. Finally, Janus Henderson Group PLC increased its position in Scholar Rock by 26.1% during the first quarter. Janus Henderson Group PLC now owns 2,236,837 shares of the company’s stock worth $109,891,000 after acquiring an additional 462,669 shares during the period. Institutional investors own 91.08% of the company’s stock.

More Scholar Rock News

Investors following SRRK have been watching these news items:

• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS forecast to a loss of $0.75 from $0.78 and its FY2026 forecast to a loss of $3.23 from $3.30. The firm maintained its Buy rating and $70 price target. Analyst outlook
• Positive Sentiment: Scholar Rock’s Q3 loss of $0.81 per share was narrower than the cited consensus estimate, and the company reported its first product revenue—potentially signaling early commercial progress. Q3 results
• Negative Sentiment: HC Wainwright sharply reduced EPS estimates for FY2027–FY2030: its FY2027 loss estimate increased to $2.66 from $1.95, and it moved FY2029 from projected earnings of $0.47 to a loss of $0.12. Its FY2030 profit estimate was cut to $1.00 from $1.44. These weaker longer-term expectations may weigh on the outlook despite the retained Buy rating.

About Scholar Rock

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.